Cancer Research Cancer Epigenetics EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldman, A. L.
Right arrow Articles by Libutti, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldman, A. L.
Right arrow Articles by Libutti, S. K.
[Cancer Research 60, 1503-1506, March 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Antiangiogenic Gene Therapy of Cancer Utilizing a Recombinant Adenovirus to Elevate Systemic Endostatin Levels in Mice

Andrew L. Feldman, Nicholas P. Restifo, H. Richard Alexander, David L. Bartlett, Patrick Hwu, Prem Seth and Steven K. Libutti1

Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892 [A. L. F., N. P. R., H. R. A., D. L. B., P. H., S. K. L.]; Human Gene Therapy Research Institute, Des Moines, IA 50309 [P. S.]

Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting antiangiogenic genes to tumor tissue specifically. Previously reported gene therapy approaches in mice have achieved peak circulating endostatin levels of 8–33 ng/ml. Here we report plasma endostatin levels of 1770 ng/ml after administration of a recombinant adenovirus. Growth of MC38 adenocarcinoma, which is relatively resistant to adenoviral infection, was inhibited by 40%. These findings encourage gene delivery approaches that use the host as a "factory" to produce high circulating levels of antiangiogenic agents.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
N. Xu, Y.-s. Wang, W.-b. Pan, B. Xiao, Y.-j. Wen, X.-c. Chen, L.-j. Chen, H.-x. Deng, J. You, B. Kan, et al.
Human {alpha}-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice
Mol. Cancer Ther., June 1, 2008; 7(6): 1588 - 1597.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. K. Greene, S. Kim, G. F. Rogers, S. J. Fishman, B. R. Olsen, and J. B. Mulliken
Risk of Vascular Anomalies With Down Syndrome
Pediatrics, January 1, 2008; 121(1): e135 - e140.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, J. Xu, J. Lawler, E. Terwilliger, and S. Parangi
Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin
Clin. Cancer Res., July 1, 2007; 13(13): 3968 - 3976.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Zhang, M. Nie, J. Sham, C. Su, H. Xue, D. Chua, W. Wang, Z. Cui, Y. Liu, C. Liu, et al.
Effective Gene-Viral Therapy for Telomerase-Positive Cancers by Selective Replicative-Competent Adenovirus Combining with Endostatin Gene
Cancer Res., August 1, 2004; 64(15): 5390 - 5397.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. A. Wickstrom, K. Alitalo, and J. Keski-Oja
An Endostatin-derived Peptide Interacts with Integrins and Regulates Actin Cytoskeleton and Migration of Endothelial Cells
J. Biol. Chem., May 7, 2004; 279(19): 20178 - 20185.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
I. A. Bhutto, S. Y. Kim, D. S. McLeod, C. Merges, N. Fukai, B. R. Olsen, and G. A. Lutty
Localization of Collagen XVIII and the Endostatin Portion of Collagen XVIII in Aged Human Control Eyes and Eyes with Age-Related Macular Degeneration
Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1544 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
V Schmitz, L Wang, M Barajas, C Gomar, J Prieto, and C Qian
Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice
Gut, April 1, 2004; 53(4): 561 - 567.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. H. DEININGER, W. A. WYBRANIETZ, F. T.C. GRAEPLER, U. M. LAUER, R. MEYERMANN, and H. J. SCHLUESENER
Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway
FASEB J, July 1, 2003; 17(10): 1267 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
A. Reijerkerk, L. O. Mosnier, O. Kranenburg, B. N. Bouma, P. Carmeliet, T. Drixler, J. C.M. Meijers, E. E. Voest, and M. F.B.G. Gebbink
Amyloid Endostatin Induces Endothelial Cell Detachment by Stimulation of the Plasminogen Activation System
Mol. Cancer Res., June 1, 2003; 1(8): 561 - 568.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Calvo, A. L. Feldman, S. K. Libutti, and J. E. Green
Adenovirus-mediated Endostatin Delivery Results in Inhibition of Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice
Cancer Res., July 15, 2002; 62(14): 3934 - 3938.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
E Robak, A Wozaniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak
Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus
Lupus, June 1, 2002; 11(6): 348 - 355.
[Abstract] [PDF]

Home page
 Neuro Oncol DukeHome page
D. R. Sorensen, T.-A. Read, T. Porwol, B. R. Olsen, R. Timpl, T. Sasaki, P. O. Iversen, H. B. Benestad, B. K. L. Sim, and R. Bjerkvig
Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma
Neuro-oncol, January 1, 2002; 4(1): 1 - 8.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
S. Ponnazhagan, D. T. Curiel, D. R. Shaw, R. D. Alvarez, and G. P. Siegal
Adeno-associated Virus for Cancer Gene Therapy
Cancer Res., September 1, 2001; 61(17): 6313 - 6321.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
T.-A. Read, M. Farhadi, R. Bjerkvig, B. R. Olsen, A. M. Rokstad, P. C. Huszthy, and P. Vajkoczy
Intravital Microscopy Reveals Novel Antivascular and Antitumor Effects of Endostatin Delivered Locally by Alginate-encapsulated Cells
Cancer Res., September 1, 2001; 61(18): 6830 - 6837.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. L. Feldman, H. R. Alexander, S. M. Hewitt, D. Lorang, C. E. Thiruvathukal, E. M. Turner, and S. K. Libutti
Effect of Retroviral Endostatin Gene Transfer on Subcutaneous and Intraperitoneal Growth of Murine Tumors
J Natl Cancer Inst, July 4, 2001; 93(13): 1014 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Mori, A. Ando, P. Gehlbach, D. Nesbitt, K. Takahashi, D. Goldsteen, M. Penn, C. T. Chen, K. Mori, M. Melia, et al.
Inhibition of Choroidal Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin
Am. J. Pathol., July 1, 2001; 159(1): 313 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, March 22, 2001; (2001) 81615298.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
A. L. Feldman, L. Tamarkin, G. F. Paciotti, B. W. Simpson, W. M. Linehan, J. C. Yang, W. E. Fogler, E. M. Turner, H. R. Alexander Jr., and S. K. Libutti
Serum Endostatin Levels Are Elevated and Correlate with Serum Vascular Endothelial Growth Factor Levels in Patients with Stage IV Clear Cell Renal Cancer
Clin. Cancer Res., December 1, 2000; 6(12): 4628 - 4634.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, April 10, 2001; 98(8): 4605 - 4610.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.